Search Results - "Rajicic, Natasa"

Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group by Sherman, Kenneth E., Rouster, Susan D., Chung, Raymond T., Rajicic, Natasa

“…Hepatitis C virus (HCV) has emerged as an important etiologic agent of liver injury and failure in patients infected with human immunodeficiency virus (HIV)…”
Get full text

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients by Funderburg, Nicholas, Kalinowska, Magdalena, Eason, James, Goodrich, James, Heera, Jayvant, Mayer, Howard, Rajicic, Natasa, Valdez, Hernan, Lederman, Michael M

“…Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated…”
Get full text

A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS by Marra, Christina M, Rajicic, Natasa, Barker, David E, Cohen, Bruce A, Clifford, David, Donovan Post, M Judith, Ruiz, Armando, Bowen, Brian C, Huang, Meei-Li, Queen-Baker, Jennie, Andersen, Janet, Kelly, Sue, Shriver, Sharon

“…To assess the safety, tolerability and effect of cidofovir for HIV-1 associated progressive multifocal leukoencephalopathy. Prospective, open-label study in…”
Get full text

Psychometric assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone by Pleil, Andreas M, Kimel, Miriam, McCormack, Julie, Rajicic, Natasa, Hey-Hadavi, Judith

“…To examine the psychometric properties of the Injection Pen Assessment Questionnaire (IPAQ) including the following: 1) item and scale characteristics (e.g.,…”
Get full text

Identification and interpretation of longitudinal gene expression changes in trauma by Rajicic, Natasa, Cuschieri, Joseph, Finkelstein, Dianne M, Miller-Graziano, Carol L, Hayden, Douglas, Moldawer, Lyle L, Moore, Ernest, O'Keefe, Grant, Pelik, Kimberly, Warren, H Shaw, Schoenfeld, David A

“…The relationship between leukocyte gene expression and recovery of respiratory function after injury may provide information on the etiology of multiple organ…”
Get full text

Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-Month, single-arm, open-label clinical trial in patient-caregiver dyads by Hey-Hadavi, Judith, MD, Pleil, Andreas, PhD, Deeb, Larry C., MD, Fuqua, John S., MD, Silverman, Lawrence A., MD, Reiner, Barry, MD, Newfield, Ron, MD, Rajicic, Natasa, ScD, Wajnrajch, Michael P., MD, Cara, Jose F., MD

“…Abstract Background: Improved ease of use of drug-delivery devices may enhance compliance. Development of an easier-to-use device for administration of…”
Get full text

Randomized Phase II Trial of Atovaquone with Pyrimethamine or Sulfadiazine for Treatment of Toxoplasmic Encephalitis in Patients with Acquired Immunodeficiency Syndrome: ACTG 237/ANRS 039 Study by Chirgwin, Keith, Hafner, Richard, Leport, Catherine, Remington, Jack, Andersen, Janet, Bosler, Elizabeth M., Roque, Clemente, Rajicic, Natasa, McAuliffe, Vincent, Morlat, Philippe, Jayaweera, D. T., Vilde, Jean-Louis, Luft, Benjamin J.

“…In this international, noncomparative, randomized phase II trial, we evaluated the effectiveness and tolerance of atovaquone suspension (1500 mg orally twice…”
Get full text

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial by Laffin, Luke J, Rodman, David, Luther, James M, Vaidya, Anand, Weir, Matthew R, Rajicic, Natasa, Slingsby, B T, Nissen, Steven E

“…Excess aldosterone production contributes to hypertension in both classical hyperaldosteronism and obesity-associated hypertension. Therapies that reduce…”
Get full text

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY by van der Lely, A. J, Biller, Beverly M. K, Brue, Thierry, Buchfelder, Michael, Ghigo, Ezio, Gomez, Roy, Hey-Hadavi, Judith, Lundgren, Frida, Rajicic, Natasa, Strasburger, Christian J, Webb, Susan M, Kołtowska-Häggström, Maria

“…Context: Pegvisomant is a GH receptor antagonist. The ACROSTUDY is a global safety surveillance study of long-term treatment of acromegaly with pegvisomant…”
Get full text

A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk by Patel, Nitin R., Ankolekar, Suresh, Antonijevic, Zoran, Rajicic, Natasa

“…We describe a value‐driven approach to optimizing pharmaceutical portfolios. Our approach incorporates inputs from research and development and commercial…”
Get full text

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2 by HARDY, W. David, GULICK, Roy M, MAYER, Howard, FÄTKENHEUER, Gerd, NELSON, Mark, HEERA, Jayvant, RAJICIC, Natasa, GOODRICH, James

“…Maraviroc, the first approved CCR5 antagonist, demonstrated 48-week safety and virologic efficacy in CCR5-tropic HIV-infected, treatment-experienced patients;…”
Get full text

The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN) by Haddad, Robert I., Harrington, Kevin Joseph, Licitra, Lisa F., Psyrri, Amanda, Saba, Nabil F., Rajicic, Natasa, Balsara, Binaifer, Kurman, Michael R., Scholz, Catherine Rose, Gualberto, Antonio, Ho, Alan Loh

“…Abstract only TPS6593 Background: HRAS mutations define a unique molecular subset of ~ 5% of HNSCC. Evidence suggests that these tumors respond poorly to…”
Get full text

Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia by Clifton, Peter, Sullivan, David, Baker, John, Schwabe, Christian, Thackwray, Susan, Scott, Russell, Hamilton, James, Chang, Ting, Given, Bruce, San Martin, Javier, Melquist, Stacey, Rajicic, Natasa, Watts, Gerald F, Goldberg, Ira J, Gaudet, Daniel, Knowles, Josh W, Hegele, Robert A, Ballantyne, Christie M

“…BackgroundHypertriglyceridemia (HTG) increases the risk of acute pancreatitis and atherosclerosis. In a Phase 1 study (NCT03783377), single subcutaneous doses…”
Get full text

Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia by Watts, Gerald F, Schwabe, Christian, Scott, Russell, Gladding, Patrick, Sullivan, David, Baker, John, Clifton, Peter, Hamilton, James, Given, Bruce, San Martin, Javier, Melquist, Stacey, Chang, Ting, Rajicic, Natasa, Goldberg, Ira J, Gaudet, Daniel, Knowles, Joshua W, Hegele, Robert A, Ballantyne, Christie M

“…BackgroundAngiopoietin-like protein 3 (ANGPTL3) regulates triglyceride (TG) and lipoprotein (LP) metabolism by inhibiting liver and endothelial LP lipases and…”
Get full text

Occult hepatitis B in HIV-infected patients by SHIRE, Norah J, ROUSTER, Susan D, RAJICIC, Natasa, SHERMAN, Kenneth E

“…Prevalence of hepatitis B virus (HBV) markers, including occult HBV, has not been described in diverse cohorts among HIV-infected patients. The objective of…”
Get full text

CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2 by Asmuth, David M, Goodrich, James, Cooper, David A, Haubrich, Richard, Rajicic, Natasa, Hirschel, Bernard, Mayer, Howard, Valdez, Hernan

“…OBJECTIVES:To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients…”
Get full text

Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial by Sattler, Fred R, Rajicic, Natasa, Mulligan, Kathleen, Yarasheski, Kevin E, Koletar, Susan L, Zolopa, Andrew, Alston Smith, Beverly, Zackin, Robert, Bistrian, Bruce

“…BACKGROUND: HIV patients with wasting are at increased risk of opportunistic complications and fatality. OBJECTIVE: We hypothesized that augmenting dietary…”
Get full text

A test for the relationship between a time-varying marker and both recovery and progression with missing data by Schoenfeld, David A., Rajicic, Natasa, Ficociello, Linda H., Finkelstein, Dianne M.

“…For clinical studies of chronic diseases, patients are followed to determine whether treatment results in either improvement or decline in their clinical…”
Get full text

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience by Wajnrajch, Michael, Gomez, Roy, Hey-Hadavi, Judith, Kelepouris, Nicky, van der Lans, Joli, Camacho-Hubner, Cecilia, Cara, Jose, Rajicic, Natasa, Rao Valluri, Srinivas, Fleseriu, Maria, Salvatori, Roberto, Brue, Thierry, Ghigo, Ezio, Palladino, Andrew

“…ACROSTUDY is an open-label, non-interventional post-authorization safety study (PASS) that began in 2004 to evaluate safety in at least 1000 acromegaly…”
Get full text

A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing by Counts, Debra R, Silverman, Lawrence A, Rajicic, Natasa, Geffner, Mitchell E, Newfield, Ron S, Thornton, Paul, Carakushansky, Mauri, Escobar, Oscar, Rapaport, Robert, Levitsky, Lynne, Rotenstein, Deborah, Hey-Hadavi, Judith, Wajnrajch, Michael P

“…Growth hormone (GH) treatment regimens for children with non-GH-deficient, idiopathic short stature (ISS) have not been optimized. To compare the efficacy,…”
Get more information